Background: Despite several new medications being Food and Drug Administration-approved for overactive bladder (OAB) and new prescription drug payment programs, there are limited population-based data regarding OAB medication use among older adults.
O veractive bladder syndrome (OAB) is defined as urinary urgency, which can occur with or without urinary incontinence, and often occurs with frequency or nocturia. 1, 2 These OAB-related symptoms negatively impact quality of life, 3, 4 affect both women (13%-17%) and men (11%-16%), and are most prevalent in older adults. [3] [4] [5] First-line pharmacotherapy for OAB includes antimuscarinics. Two prominent antimuscarinics are oxybutynin and tolterodine, which were approved by the United States Food and Drug Administration in 1975 and 1998, respectively. 6, 7 More recently, several new antimuscarinics (trospium, solifenacin, darifenacin, fesoterodine) and 1 β 3 -adrenergic-agonist (mirabegron) were Food and Drug Administration-approved for OAB 7 (Table S1 .1, Supplemental Digital Content 1, http://links. lww.com/MLR/B515). These new medications have recently granted patients the possible availability of alternative pharmacotherapeutic options for OAB. In addition, in 2006, large nationwide retail pharmacy chains introduced $4 generic programs offering $4/$10 prices for 30/90 days' supply of > 200 generic prescription medications, including immediate-release (IR) oxybutynin tablets. [8] [9] [10] Subsequently, the costs of OAB therapy have changed over time, coinciding with new payment plans designed to increase patients' access to medication.
Nationally representative cross-sectional data from 2009 to 2010 showed concentrated OAB-related prescribing in older adults, mostly for oxybutynin, tolterodine, and solifenacin. 11, 12 However, no published data describe OAB-related time trends for utilization or payments, and no studies are recent enough to have assessed mirabegron. Data are needed regarding the impact of these population-level changes (ie, newly available medications, payment plans) on OAB-related prescribing and medication payments. Furthermore, the absence of studies in older adults is particularly concerning, given the potential risks due to anticholinergic properties of antimuscarinics (eg, cognition, constipation). [13] [14] [15] [16] [17] [18] In this study of older adults in the United States, we sought to examine: (1) time trends for dispensing rates of OAB-related prescriptions, potentially brought about by newly emerging OAB medications and $4 generic programs; (2) dispensing rate differences by age and sex; and (3) time trends in beneficiary and insurer payments for OAB medications.
METHODS

Setting and Participants
Data for this analysis were drawn from Truven Health Analytics' Medicare Supplemental Database (2017 Truven Health Analytics Inc., all rights reserved), which contain deidentified individual-level enrollment and administrative health care claims data for inpatient, outpatient, and prescription drug services in the United States from 2000 to 2015, and have been adjudicated and validated by Truven Health. 19, 20 These data include Medicare-covered and employer-covered portions of health care claims for individuals enrolled in Medicare who receive Medicare Supplemental insurance (henceforth, "Medigap") from their employer or former employer, aggregated from over 300 large employers across the United States. 19, 20 We restricted this analysis to individuals age 65-104 years.
We analyzed enrollment data and claims for dispensed prescriptions for 7 different types of IR and extended-release (ER) medications for OAB: oxybutynin; tolterodine; trospium; darifenacin; solifenacin; fesoterodine; and mirabegron. We identified National Drug Codes for these medications by searching their generic names and anatomical therapeutic chemical codes in the National Drug Data File-NDDF Plus (First Databank, www.firstdatabank.com/) and Red Book data (Truven Health Analytics Inc.).
Measures
The primary measure of interest was the dispensing rate (henceforth, "rate") for each OAB medication. The numerator of the rate was the number of dispensed prescriptions, where we defined 1 "prescription" as a 1-month (ie, 30-day) supply of medication; the denominator of the rate was the number of person-months (equal to 30 person-days) of Medigap prescription drug coverage (footnotes, Table 1) .
For each medication, we estimated stratum-specific rates per 1000 person-months by calendar time (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) , sex (male/female), year-specific age (65-104), and geography, with 99% confidence intervals (CI) assuming a Poisson distribution. 22, 23 Geography was assessed using a 52-level variable (50 states, District of Columbia, Puerto Rico) and a 4-level variable (Midwest, Northeast, South, West Census regions).
In addition to rates, we assessed payments for dispensed OAB medications. For each claim, we calculated payments per prescription (ie, 1-month supply) in US dollars ($). We measured payments in 2 ways: (1) beneficiary payments (deductible, coinsurance, copayment, and coordination of benefits); and (2) total payments (beneficiary payments plus all postdiscount payments by the insurer). We excluded claims for total payments ≤ $0 (0.6%) and negative beneficiary payments (0.02%). 24 To account for inflation during 2000-2015, payments were adjusted to dollar amounts in the year 2015, using the "Medical care" expenditure category of the Consumer Price Index. 21 
Interrupted Time-series Analysis of Dispensing Rates
To estimate time trends in dispensing for each medication, we conducted an interrupted time-series analysis, 25, 26 which is a common quasiexperimental method to assess impacts of policy changes or other population-level changes. Below, we describe our approach in detail.
First, we defined 52 weeks in each year based on 7-day increments. Second, for each week from 2000 to 2015 (n = 832 wk), we estimated the dispensing rate 23 for all medications combined and separately for each medication. To control for year-to-year variation in the geographic distribution and types of insurance plans included in Truven's Medigap database, we estimated standardized rates 23, 27 for each week, which rendered time trends independent of sampling artifacts in the database (Text, Supplemental Digital Content 2, http://links.lww.com/MLR/B515).
Third, we identified 12 interruptions during 2000-2015 when new medications or payment plans were introduced at the population level in the United States, which could have altered dispensing of medications for OAB (Table 2) . Some prespecified interruptions were nearly concurrent; to reduce complexity and minimize spurious results, we consolidated interruptions occurring within 20 weeks (footnotes, Table 2 ). As a result, our primary interrupted time-series analysis explicitly considered 7 interruption timepoints. In sensitivity analysis, we also assessed the additional impacts of Beers Criteria updates in 2003 and 2012 14, 28 and Medicare Part D in 2006 29 ; we did not assess the most recent Beers criteria update in October 2015 15 due to insufficient data for modeling.
Finally, using ordinary least squares, we specified medication-specific segmented linear regression models for standardized dispensing rates to estimate the trend (and 99% CI) between every pair of neighboring interruptions. We controlled potential confounding by seasonality using a transformed cosine periodic function. 30, 31 To account for error autocorrelation over time, we used Durbin-Watson statistical tests 32 (α = 0.05) to specify autoregressive parameters in our models for lags up to 14 months. Our models did not include parameters for level changes between adjacent segments, based on our hypothesis that interruptions would gradually affect dispensing. 33 For each medication that entered the market during the study period, in the week preceding its earliest observed claim in the database, we forced its intercept to 0. Table 2 enumerates all of our specific a priori hypotheses for the interrupted time-series analysis. Broadly, based on principles of innovation diffusion, we first hypothesized that new medications entering the market would lead to downward trend deflections (ie, gradual changes over time) for other medications they might replace. We expected greater downward deflections for medications sharing the same release mechanism (eg, solifenacin would induce negative deflections for other ER medications). Second, for new medications belonging to a larger group, we hypothesized upward trend deflections for that medication group. For example, ER-oxybutynin transdermal gel was introduced in 2009 after many prior formulations of ERoxybutynin had long existed; we expected the addition of the transdermal gel formulation to increase treatment rates for ER-oxybutynin. After the introduction of $4 generic programs, we expected many IR oxybutynin tablets prescriptions to be paid for out-of-pocket by beneficiaries, leading Medicare data to lack complete data on IR oxybutynin dispensing; therefore, our third hypothesis was that $4 generic programs would be associated with decreasing trends in claims data for IR oxybutynin and other-IR medications (tolterodine and trospium).
Age and Sex Differences
We used stratified analysis methods 23 to estimate rate differences by age and sex for all medications combined, averaged over the study period. To account for correlation between age and sex, we report rate differences comparing age groups separately for women and men, and rate differences comparing women versus men separately by age. We explicitly did not estimate rate ratios because they depend on the referent rate, which was highly variable across age groups. We estimated 99% CIs using percentiles from 2000 bootstrap resamples. 34 
Payments Analysis
We used percentiles to summarize beneficiary and total payments per prescription, and compared payments across calendar time, sex, age, and geography. Results for age and sex were averaged over the study period. To control for potential confounding by geography, we standardized payment distributions (Text, Supplemental Digital Content 2, http:// links.lww.com/MLR/B515). Whereas we used interrupted time-series methods to assess explicit hypotheses related to OAB medication dispensing, our analysis of payments lacked hypotheses for specific time-related impacts, and is therefore exploratory in nature.
Data management and statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc.; Cary, NC). Segmented regression models were implemented using SAS PROC AUTOREG and the %AR macro in SAS PROC MODEL, which enable the investigator to identify autoregressive parameters and obtain estimates with SEs for any linear combination of parameters from a model with autocorrelated errors. Graphics were created using R version 3.3.2 (R Foundation for Statistical Computing; Vienna, Austria). This study was reviewed and exempted from ethics approval by the institutional review board at the University of North Carolina at Chapel Hill (10-0153).
RESULTS
During 2000-2015, we assessed 9,477,061 individuals age 65-104 over 421,122,388 person-months of Medigap prescription drug coverage; the 5th-25th-50th-75th-95th percentiles of years with Medigap coverage were 0.2-1.0-2.7-5.0-11.0. Approximately 1 in 12 older adults in this population filled at least 1 OAB-related prescription (771,609 individuals, 13,863,998 total OAB-related fills). Oxybutynin and tolterodine, the only OAB medications available until 2004, 7 were the most common OAB medications during 2000-2015 (34% and 42% of dispensed prescriptions, respectively). By 2015, after several new medications became available, oxybutynin and tolterodine together accounted for 56% of dispensed prescriptions; solifenacin (20%) and mirabegron (12%) were also common. Total payments for OAB medications during 2000-2015 exceeded $1.6 billion, ∼2% of all prescription drug spending in this population. Table 1 shows crude subgroup-specific rates and payment summaries. Figure 1 shows standardized dispensing rates for each OAB medication group, and seasonality-adjusted segmented trend estimates from our interrupted time-series analysis. Trend estimates were precise at α = 0.01 (Table S3. Other hypothesized interruptions (ie, newly available ERoxybutynin patches, IR/ER-trospium, ER-fesoterodine) had negligible impacts on dispensing of other medications (Fig. 1) . A sensitivity analysis, which added 3 new interruptions for Beers criteria updates and Medicare Part D to the original 7 interruptions in the primary analysis, had minor impacts on time trends for each medication group (Fig. S4.1 , Supplemental Digital Content 4, http://links.lww.com/MLR/B515).
Interrupted Time-series Analysis of Dispensing Rates
Age and Sex Differences
Age-specific rates ranged from 19.0 to 53.4 prescriptions per 1000 person-months. For both men and women, dispensing rates for OAB increased with increasing age (Fig. 2) , peaking at age 90 (53.4 per 1000 person-months; 99% CI, 53.1-53.7). Past age 90, rates declined steadily with increasing age among both women and men. Rate differences between women and men were 22.0 per 1000 person-months on an average; however, rate differences varied across the age range, increasing from 19.2 (age 65) to a peak difference of 24.8 (age 85). Over age 90, rates decreased more for women than men, thus reducing rate differences at the highest ages. Rate differences by age and sex were stable over calendar time, and medication-specific rates and trends over time were proportional by age and sex (data not shown). Figure 3 shows time trends for percentiles of beneficiary and total payments per prescription. Beneficiary payments per prescription were stable during 2000-2011 (Fig. 3A) . Although the vast majority of beneficiary payments remained unchanged through 2015, those in the top 10% more than doubled between 2012-2015 (Fig. 3A) . During the first half of the study period, total payments per prescription were stable over time, shown by the largely horizontal Loess curves during [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] (Fig. 3B) . Between 2008-2015, there were marginal increases in median total payments, from $125 to $150 per prescription, but the gap between upper and lower percentiles of total payments widened. Beneficiary and total payments remained stable for IR medications across the study period (Fig. S5.1 , Supplemental Digital Content 5, http://links.lww.com/MLR/B515). Beneficiary and total payments increased over time for all ER medications except ERoxybutynin tablets (Figs. S5.2-S5 .3, Supplemental Digital Content 5, http://links.lww.com/MLR/B515). A sensitivity analysis of payments over time, which used stratified analyses to assess potential confounding by insurance type and data supplier, did not affect our interpretation of results (data not shown).
Payments for OAB Medications
Beneficiary and total payments were similar between sexes and across age groups. The only exception concerned individuals with the highest 5% of beneficiary payments for OAB medications, in whom higher age was associated with higher beneficiary payments per prescription, for women and men. Between ages 65-74, the 95th percentile beneficiary payment ranged $61-$65 per prescription; from ages 75-99, the 95th percentile beneficiary payment per prescription increased monotonically by $13 with each decade of age (99% CI, $11-$15), up to $96 per prescription at age 99.
DISCUSSION
In this population-based study of health care claims data during 2000-2015 on older adults in the United States, we observed increases in prescription drug dispensing for OAB from 2000-2007 as new medications became available (ie, ER-tolterodine, darifenacin, and solifenacin). Oxybutynin and tolterodine were the most prominent medications in the early years of the study, but their rates decreased over time as new alternatives darifenacin, solifenacin, and mirabegron became more widely dispensed. Compared with the significant impacts of certain emerging medications on time trends, $4 generic programs, Beers criteria, and Medicare Part D had nominal effects on OAB medication dispensing rates in this population. Rates increased with increasing age, were highest between age 85-90 for both women and men, and were higher for women than men at all ages. We observed stable beneficiary and total payment levels until the latter years of the study period, when the most expensive prescriptions became costlier to the beneficiary and insurer over time. Payment increases over time were driven by all ER medications except ER-oxybutynin tablets. By 2015, 25% of total payments for OAB medications exceeded $250 per reimbursed dispensed prescription.
Our novel results provide key information on OAB medication dispensing over time, specifically regarding medication-specific trends being impacted by new alternatives. ER medications accounted for an increasing share of OAB dispensing over time (to 78% by 2015), potentially due in part to their lower adverse event and discontinuation rates versus IR. 35, 36 Regarding ER medications, darifenacin and solifenacin debuted in 2005; as their rates increased alongside decreasing rates for ER-oxybutynin and tolterodine, overall rates were stable through 2015. These data suggest that ER medications released after 2005 may have served, to some degree, as therapeutic replacements for oxybutynin and tolterodine.
Comprehensive systematic reviews have found that antimuscarinic OAB medications exhibit similar intended treatment effects. 36, 37 Trospium, despite its unique structural advantage over other antimuscarinics that it cannot cross the blood-brain barrier 38 (and thus should induce less anticholinergic effect), never became highly prevalent in this study population.
In contrast to trospium, these new findings about mirabegron have potential implications for clinicians, researchers, and policy-makers; these results underscore the ongoing need for adherence, effectiveness, and safety studies that account for time-related shifts in dissemination of each OAB medication. Given ongoing concerns about antimuscarinic-associated anticholinergic effects and subsequent adverse effects in OAB patients, there is potential for mirabegron to fill a decades-long therapeutic gap, as mirabegron -a β 3 -adrenergic-agonist-is the only nonantimuscarinic treatment alternative. 7, 16, 39 Uptake of mirabegron (2012) resembled that of solifenacin (2005) (2006) (2007) (2008) , despite mirabegron entering the market later with more contemporary treatment alternatives compared with solifenacin. If real-world treatment effectiveness of mirabegron is equivalent/superior to ER antimuscarinics, patients might benefit more from mirabegron due in part to its nonanticholinergic properties. Recent increased dissemination of mirabegron could signal of relative treatment benefit for mirabegron in some patients.
To investigate this possibility and further inform clinical guidelines for OAB medications, future research should track utilization patterns of mirabegron (and all other OAB medications) beyond 2015, and assess their impact on patient outcomes. In addition, future studies should consider the timevarying nature of branded-versus-generic status when comparing medications, as well as the recent introduction of over-thecounter oxybutynin 40 and posterior tibial nerve stimulation. 41 Our results indicate a negligible impact of $4 generic programs on OAB dispensing in this insured population. Given that data on cash payments for prescription drugs are missing from claims data, 42 we consider 2 hypothetical explanations for this result: (1) $4 generic program did not impact how these insured patients accessed OAB medication; or (2) OAB treatment prevalence increased after 2006, but only among Medigap-insured patients who initiated treatment after $4 generics became available. For explanation #2 to be valid, 2 necessary conditions apply to those patients: (i) their symptom onset was after 2006 or their physician withheld pharmacotherapy until after 2006; and (ii) they opted to pay $4 in cash despite their ability to acquire equivalent medication through their insurer for $7 (interquartile range, $4-$14) (Fig. S5.1 , Supplemental Digital Content 5, http://links. lww.com/MLR/B515). We consider explanation #1 more plausible; however, our conclusion would be far less tenable had more medications besides IR oxybutynin been in $4 generics programs. In this light, future research should assess changes over time and across populations in the impact of $4 generics programs. 43 Dispensing rates increased with age, likely reflecting the fact that OAB prevalence increases with age. 44 In addition, dispensing rates were higher for women than men, which extends prior symptom-centered evidence that women suffer more than men from "wet" OAB with urgency urinary incontinence. 44, 45 These data are striking amid concerns over potential adverse events of antimuscarinics, especially among older adults, [16] [17] [18] and recent updates to Beers criteria for potentially inappropriate prescribing in older adults. 14, 15, 28 These new payment data are important for clinical and policy decision-making concerning OAB medications. Our results demonstrate significant cost differences to Medigap beneficiaries and insurers depending on the specific OAB medication that was prescribed. As evidence emerges concerning comparative effectiveness and safety of these medications, the cost gradient of these medications may become an increasingly critical consideration for clinical treatment decisions and payment policies.
Given that health care expenditures for Medigap beneficiaries exceed Medicare-only by 24%, 46 it remains unclear whether expenditure differences result from unnecessary health care utilization among Medigap beneficiaries. 47, 48 Future research should consider how drug-specific payment differences manifest across insurance subgroups, and should leverage our novel real-world data covering 16 years of payments for OAB medications in the Medigap population.
Limitations of our study should be considered when interpreting results. First, these data reflect dispensed prescriptions. This study therefore could not examine medication consumption or treatment adherence. Second, we lacked data on free samples and redeemed prescriptions that were not reimbursed by health insurance. 42, 49, 50 As mentioned above, this missing data problem limits our interpretation of $4 generic programs' impact. Instead of the preferable ability to explicitly enumerate IR oxybutynin prescriptions paid for with cash, we substituted a priori assumptions-which we consider plausible-about how an impact would have occurred for this drug class in the Medigap population. Third, this study assessed older adults with Medigap prescription drug coverage through their employer or former employer; subsequently, due to potentially unique demographic, clinical, and policy-related characteristics in the Medigap population, our results may not be generalizable to the larger Medicare population, those on Medicaid, or the uninsured. Fourth, this study did not exclude patients with dementia or other conditions associated with high anticholinergic load; given that these individuals may have had contraindications for antimuscarinic therapy, our results may underestimate dispensing rates among those considered eligible for treatment. Fifth, these health care claims data lacked detailed information on OAB symptoms and severity, which limited our ability to estimate rates in clinically meaningful subgroups.
This study has several strengths. We provide new population-based estimates of OAB medication dispensing for Medigap enrollees across the United States with prescription drug coverage. The databases that we analyzed include accurate individual-level data on Medigap enrollment and Medicare-covered and employer-covered portions of dispensed prescriptions (date, days supplied, medication, and payments). Our interrupted time-series analysis examined a critical 16-year period of changes in OAB treatment; several new medications became available, nationwide pharmacy chains introduced $4 generic programs, Medicare Part D was introduced, and concern surged regarding anticholinergic effects in older adults. In addition, to reduce potential confounding or unaccounted cointervention effects on time trend estimates for rates and payments, we standardized for changes over time in the geographic distribution and types of insurance plan in the databases. 26, 27 
CONCLUSIONS
Overall dispensing rates for OAB medications among older adults in the United States increased during 2000-2007 as new medications became available, then stabilized through 2015. Medication-specific rates were dynamic, however, and were impacted by several new OAB medications that emerged during the study period. Dispensing rates were highest for women and adults age 85-90. Beneficiary payments for OAB medications were stable during 2000-2015, but large disparities emerged in total payments during the latter half of the study, driven largely by newly available ER medications. These new data inform translational research into patient outcomes and payment structures related to OAB medications, which are especially important for the older adult population.
